Lupin Launches Generic Dasatinib in U.S., Targeting $930M Market
Event summary
- Lupin launched Dasatinib Tablets in the U.S. in February 2026, following FDA ANDA approval.
- The product is bioequivalent to Bristol-Myers Squibb's Sprycel, with estimated annual U.S. sales of $930M (IQVIA MAT Oct 2025).
- Dasatinib is indicated for treating various forms of leukemia, including pediatric patients.
- The launch was developed in partnership with Canadian pharmaceutical manufacturer Pharmascience Inc.
The big picture
Lupin's entry into the Dasatinib market represents a strategic move to capitalize on the growing demand for affordable cancer treatments. The $930M market opportunity underscores the significance of generic competition in the oncology space, particularly for chronic conditions like leukemia. This launch aligns with Lupin's broader strategy of expanding its complex generics portfolio in high-value therapeutic areas.
What we're watching
- Market Penetration
- How quickly Lupin can capture market share from Bristol-Myers Squibb's Sprycel in the U.S.
- Regulatory Compliance
- Whether Lupin can maintain regulatory approvals amid potential patent disputes.
- Partnership Dynamics
- The impact of the Pharmascience partnership on Lupin's future product development and launches.
Related topics